San Diego-based Viking Therapeutics marked alone as a significant competitor in the weight loss drug marketplace in February following revealing promising information from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given like a weekly injection and in March the company un